Literature DB >> 25841959

Effect of Buffered 4% Lidocaine on the Success of the Inferior Alveolar Nerve Block in Patients with Symptomatic Irreversible Pulpitis: A Prospective, Randomized, Double-blind Study.

Jared Schellenberg1, Melissa Drum2, Al Reader3, John Nusstein2, Sara Fowler2, Mike Beck4.   

Abstract

INTRODUCTION: Medical studies have suggested that buffering local anesthetic may increase the ability to achieve anesthesia. The purpose of this study was to determine the effect of 4% buffered lidocaine on the anesthetic success of the inferior alveolar nerve (IAN) block in patients experiencing symptomatic irreversible pulpitis.
METHODS: One hundred emergency patients diagnosed with symptomatic irreversible pulpitis of a mandibular posterior tooth randomly received a conventional IAN block using either 2.8 mL 4% lidocaine with 1:100,000 epinephrine or 2.8 mL 4% lidocaine with 1:100,000 epinephrine buffered with sodium bicarbonate in a double-blind manner. For the buffered solution, each cartridge was buffered with 8.4% sodium bicarbonate using the OnPharma (Los Gatos, CA) system to produce a final concentration of 0.18 mEq/mL sodium bicarbonate. Fifteen minutes after administration of the IAN block, profound lip numbness was confirmed, and endodontic access was initiated. Success was defined as no or mild pain (≤54 mm on a 170-mm visual analog scale) on access or instrumentation of the root canal.
RESULTS: The success rate for the IAN block was 32% for the buffered group and 40% for the nonbuffered group, with no significant difference (P = .4047) between the groups. Injection pain ratings for the IAN block were not significantly (P = .9080) different between the 2 formulations.
CONCLUSIONS: For mandibular posterior teeth, a 4% buffered lidocaine formulation did not result in a statistically significant increase in the success rate or a decrease in injection pain of the IAN block in patients with symptomatic irreversible pulpitis.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Buffered lidocaine; inferior alveolar nerve block; irreversible pulpitis; lidocaine; symptomatic irreversible pulpitis

Mesh:

Substances:

Year:  2015        PMID: 25841959     DOI: 10.1016/j.joen.2015.02.022

Source DB:  PubMed          Journal:  J Endod        ISSN: 0099-2399            Impact factor:   4.171


  6 in total

1.  Inferior Alveolar Nerve Block Injection Pain Using a Computer-Controlled Local Anesthetic Device (CCLAD): A Prospective, Randomized Study.

Authors:  Sara Fowler; Chase Crowley; Melissa Drum; Al Reader; John Nusstein; Mike Beck
Journal:  Anesth Prog       Date:  2018

2.  An Evaluation of Ibuprofen Versus Ibuprofen/Acetaminophen for Postoperative Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis and Symptomatic Apical Periodontitis.

Authors:  Alex Stamos; Melissa Drum; Al Reader; John Nusstein; Sara Fowler; Mike Beck
Journal:  Anesth Prog       Date:  2019

Review 3.  Efficacy of sodium bicarbonate buffered versus non-buffered lidocaine with epinephrine in inferior alveolar nerve block: A meta-analysis.

Authors:  Jing Guo; Kaifeng Yin; Rafael Roges; Reyes Enciso
Journal:  J Dent Anesth Pain Med       Date:  2018-06-29

4.  Nitrous Oxide/Oxygen Effect on IANB Injection Pain and Mandibular Pulpal Anesthesia in Asymptomatic Subjects.

Authors:  Ben Kushnir; Sara Fowler; Melissa Drum; John Nusstein; Al Reader; Mike Beck Dds
Journal:  Anesth Prog       Date:  2021-06-01

5.  How Successful is Supplemental Intraseptal and Buccal Infiltration Anaesthesia in the Mandibular Molars of Patients Undergoing Root Canal Treatment or Tooth Extraction?

Authors:  Giath Gazal; Rayan Bahabri; Albraa B Alolayan; Mahmod Alkayyal; Rahaf Al-Ghamdi; Ruwaa Salamah
Journal:  J Oral Maxillofac Res       Date:  2020-03-31

6.  Interventions for anesthetic success in symptomatic irreversible pulpitis: A network meta-analysis of randomized controlled trials.

Authors:  Gowri Sivaramakrishnan; Muneera Alsobaiei; Kannan Sridharan
Journal:  J Dent Anesth Pain Med       Date:  2019-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.